[新型口服头孢菌素头孢泊肟酯干混悬剂在儿童中的临床评价]
[Clinical evaluation of a new oral cephem, cefpodoxime proxetil in children].
作者信息
Meguro H, Arimasu O, Shiraishi H, Tajima T, Hiruma F, Nishimura S, Sugie N, Sugamata K, Abe T, Fujii R
机构信息
Department of Pediatrics, School of Medicine, Teikyo University.
出版信息
Jpn J Antibiot. 1989 Jul;42(7):1561-70.
Cefpodoxime proxetil (CPDX-PR, CS-807) was evaluated for its efficacy, safety and pharmacokinetics in children. CPDX-PR was effective in 93.6% of 47 cases with respiratory tract, middle ear, skin or urinary tract infections. Twice or 3 times daily administration of 3 mg/kg each was sufficient to treat streptococcal pharyngitis and Haemophilus influenzae infections. No severe adverse reaction was encountered in 52 cases treated with CPDX-PR. The serum half-life was approximately 2.17 +/- 0.24 hours after oral administration.
对头孢泊肟酯（CPDX-PR，CS-807）在儿童中的疗效、安全性及药代动力学进行了评估。CPDX-PR对47例呼吸道、中耳、皮肤或尿路感染患儿的有效率为93.6%。每日2次或3次、每次3mg/kg给药足以治疗链球菌性咽炎和流感嗜血杆菌感染。52例接受CPDX-PR治疗的患儿未出现严重不良反应。口服给药后血清半衰期约为2.17±0.24小时。
Zotero 插件